They could grow into their valuation over the next few years.

Merck's updated narrative now anchors to a slightly higher fair value estimate of about $106.62 per share, up from roughly $104.27, as analysts grow more confident in the depth and durability of its ...

Under the terms of this agreement, Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the ...

The global Merkel Cell Carcinoma (MCC) market is rapidly evolving, driven by advancements in immunotherapy and a surge in early diagnoses. Merkel cell carcinoma, a rare, aggressive skin cancer mainly ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

MARTINSRIED, Germany, Dec. 9, 2025 /CNW/ — Zydus Lifesciences Limited (including its subsidiaries and affiliates), an innovation-led life-sciences ...

Merck spent $10bn on lung disease-focused biotech Verona Pharma in July, its biggest acquisition in two years, amid concerns ...

As Big Pharma braces for a massive revenue crash when patents on blockbuster drugs expire, an unexpected player is stepping ...

Cosmo Pharmaceuticals attracted welcome attention from investors and other market watchers after coming out with topline ...

Tom Hancock, a portfolio manager at GMO, favors companies that consistently earn a high return on capital and reinvest in the ...

The company is finding ways to overcome the headwinds it will encounter in the medium term.